Citations (152)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (15)
Julia M. K. Freind, Fernando R. Beserra, Bruno S. Menezes & Daniel C. Mograbi. (2023) Therapeutic Protocols Using Ketamine and Esketamine for Depressive Disorders: A Systematic Review. Journal of Psychoactive Drugs 0:0, pages 1-17.
Read now
Read now
Jorge Valdiviezo-Oña, Lizbeth Toscano-Molina, Juan Fernando Chávez, Jonathan Elías Herrera & Clara Paz. (2023) Outcomes of usage of psychedelics by people reporting an eating disorder in clinical and non-clinical settings: a scoping review. Advances in Mental Health 0:0, pages 1-13.
Read now
Read now
Sandra J Drozdz, Akash Goel, Matthew W McGarr, Joel Katz, Paul Ritvo, Gabriella F Mattina, Venkat Bhat, Calvin Diep & Karim S Ladha. (2022) Ketamine Assisted Psychotherapy: A Systematic Narrative Review of the Literature. Journal of Pain Research 15, pages 1691-1706.
Read now
Read now
Michael D. Kritzer, Chi-Un Pae & Prakash S. Masand. (2022) Key considerations for the use of ketamine and esketamine for the treatment of depression: focusing on administration, safety, and tolerability. Expert Opinion on Drug Safety 21:6, pages 725-732.
Read now
Read now
Suresh D. Muthukumaraswamy, Anna Forsyth & Thomas Lumley. (2021) Blinding and expectancy confounds in psychedelic randomized controlled trials. Expert Review of Clinical Pharmacology 14:9, pages 1133-1152.
Read now
Read now
Luke A. Jelen & James M. Stone. (2021) Ketamine for depression. International Review of Psychiatry 33:3, pages 207-228.
Read now
Read now
Jennifer Dore, Brent Turnipseed, Shannon Dwyer, Andrea Turnipseed, Julane Andries, German Ascani, Celeste Monnette, Angela Huidekoper, Nicole Strauss & Phil Wolfson. (2019) Ketamine Assisted Psychotherapy (KAP): Patient Demographics, Clinical Data and Outcomes in Three Large Practices Administering Ketamine with Psychotherapy. Journal of Psychoactive Drugs 51:2, pages 189-198.
Read now
Read now
Leigh C Walker & Andrew J Lawrence. (2018) Investigational drug therapies in phase I and phase II clinical trials for alcohol use disorders. Expert Opinion on Investigational Drugs 27:8, pages 677-690.
Read now
Read now
Albert Garcia-Romeu & William A. Richards. (2018) Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions. International Review of Psychiatry 30:4, pages 291-316.
Read now
Read now
Jih-Heng Li, Balasingam Vicknasingam, Yuet-Wah Cheung, Wang Zhou, Adhi Wibowo Nurhidayat, Don C Des Jarlais & Richard Schottenfeld. (2011) To use or not to use: an update on licit and illicit ketamine use. Substance Abuse and Rehabilitation 2, pages 11-20.
Read now
Read now
EvgenyM. Krupitsky, AndreiM. Burakov, IgorV. Dunaevsky, TatyanaN. Romanova, TatyanaY. Slavina & AlexanderY. Grinenko. (2007) Single Versus Repeated Sessions of Ketamine-Assisted Psychotherapy for People with Heroin Dependence. Journal of Psychoactive Drugs 39:1, pages 13-19.
Read now
Read now
Eli Kolp, Harris L. Friedman, M. Scott Young & Evgeny Krupitsky. (2006) Ketamine Enhanced Psychotherapy: Preliminary Clinical Observations on Its Effectiveness in Treating Alcoholism. The Humanistic Psychologist 34:4, pages 399-422.
Read now
Read now
Harris Friedman. (2006) The Renewal of Psychedelic Research: Implications for Humanistic and Transpersonal Psychology. The Humanistic Psychologist 34:1, pages 39-58.
Read now
Read now
Karl
L.R. Jansen & Rachael Darracot-Cankovic. (2001) The Nonmedical Use of Ketamlne, Part Two: A Review of Problent Use and Dependence. Journal of Psychoactive Drugs 33:2, pages 151-158.
Read now
Read now
Karl
L.R. Jansen. (2000) A Review of the Nonmedical Use of Ketamine: Use, Users and Consequences. Journal of Psychoactive Drugs 32:4, pages 419-433.
Read now
Read now
Articles from other publishers (137)
Fahd François Hilal, Jerome Jeanblanc, Chloé Deschamps, Mickael Naassila, Olivier Pierrefiche & Sami Ben Hamida. (2024) Epigenetic drugs and psychedelics as emerging therapies for alcohol use disorder: insights from preclinical studies. Journal of Neural Transmission 131:5, pages 525-561.
Crossref
Crossref
Magdalena Więdłocha, Piotr Marcinowicz, Jan Komarnicki, Małgorzata Tobiaszewska, Weronika Dębowska, Marta Dębowska & Agata Szulc. (2024) Depression with comorbid borderline personality disorder - could ketamine be a treatment catalyst?. Frontiers in Psychiatry 15.
Crossref
Crossref
Tamar Glatman Zaretsky, Kathleen M. Jagodnik, Robert Barsic, Josimar Hernandez Antonio, Philip A. Bonanno, Carolyn MacLeod, Charlotte Pierce, Hunter Carney, Morgan T. Morrison, Charles Saylor, George Danias, Lauren Lepow & Rachel Yehuda. (2024) The Psychedelic Future of Post-Traumatic Stress Disorder Treatment. Current Neuropharmacology 22:4, pages 636-735.
Crossref
Crossref
Lisa Burback, Suzette Brémault-Phillips, Mirjam J. Nijdam, Alexander McFarlane & Eric Vermetten. (2024) Treatment of Posttraumatic Stress Disorder: A State-of-the-art Review. Current Neuropharmacology 22:4, pages 557-635.
Crossref
Crossref
Viviana D. EvansAlejandro ArenasKenneth Shinozuka, Burton J. TabaacBryce D. BeutlerKirsten CherianChelsey FasanoOwen S. Muir. (2024) Psychedelic Therapy: A Primer for Primary Care Clinicians—Ketamine. American Journal of Therapeutics 31:2, pages e155-e177.
Crossref
Crossref
Boris D. Heifets & David E. Olson. (2023) Therapeutic mechanisms of psychedelics and entactogens. Neuropsychopharmacology 49:1, pages 104-118.
Crossref
Crossref
Jennifer M. Mitchell & Brian T. Anderson. (2023) Psychedelic therapies reconsidered: compounds, clinical indications, and cautious optimism. Neuropsychopharmacology 49:1, pages 96-103.
Crossref
Crossref
David B. Yaden, Andrea P. Berghella, Peter S. Hendricks, Mary E. Yaden, Michael Levine, Julia S. Rohde, Sandeep Nayak, Matthew W. Johnson & Albert Garcia-Romeu. (2024) IUPHAR-review: The integration of classic psychedelics into current substance use disorder treatment models. Pharmacological Research 199, pages 106998.
Crossref
Crossref
Ashok DB. Vaidya. (2024) Integrative vision in cancer research, prevention and therapy. Journal of Ayurveda and Integrative Medicine 15:1, pages 100856.
Crossref
Crossref
Jamshid Ahmadi, Arash Mansoori, Seyed Hamdollah Mosavat & Amir Bazrafshan. (2023) Comparison of ketamine with buprenorphine as adjunctive therapy in the treatment of comorbid major depressive disorder and opium use disorders: A randomized controlled trial. The International Journal of Psychiatry in Medicine.
Crossref
Crossref
Kelley C. O'Donnell, Daniel E. RobertsTerence H.W. ChingGianni GlickNoam GoldwayNatalie GukasyanJamila HokansenBenjamin KelmendiStephen RossMary E. YadenChristopher Pittenger. (2023) What Is in a Name? The Many Meanings of “Psychedelic”. Psychedelic Medicine 1:4, pages 187-189.
Crossref
Crossref
Steffen Reissmann, Matthias Hartmann, Andreas Kist, Matthias E. Liechti & Kurt Stocker. (2023) Case report: Maintaining altered states of consciousness over repeated ketamine infusions may be key to facilitate long-lasting antidepressant effects: some initial lessons from a personalized-dosing single-case study. Frontiers in Psychiatry 14.
Crossref
Crossref
Harry M Griffiths. (2023) Low-dose ketamine infusions for chronic pain management: Does this qualify as evidence-based practice?. British Journal of Pain 17:5, pages 457-467.
Crossref
Crossref
Anna Ross & Jake Hawthorn. (2023) The Use of Illicit Drugs in Therapy: an Introduction. Current Addiction Reports 10:4, pages 817-824.
Crossref
Crossref
Mary G. Hornick & Ashley Stefanski. (2023) Hallucinogenic potential: a review of psychoplastogens for the treatment of opioid use disorder. Frontiers in Pharmacology 14.
Crossref
Crossref
Allison Feduccia, Gabby Agin-Liebes, Collin M. Price, Nicole Grinsell, Summer Paradise & David M. Rabin. (2023) The need for establishing best practices and gold standards in psychedelic medicine. Journal of Affective Disorders 332, pages 47-54.
Crossref
Crossref
Joost J. Breeksema, Alistair Niemeijer, Bouwe Kuin, Jolien Veraart, Eric Vermetten, Jeanine Kamphuis, Wim van den Brink & Robert Schoevers. (2023) Phenomenology and therapeutic potential of patient experiences during oral esketamine treatment for treatment-resistant depression: an interpretative phenomenological study. Psychopharmacology 240:7, pages 1547-1560.
Crossref
Crossref
Simon Zhornitsky, Henrique N. P. Oliva, Laura A. Jayne, Aza S. A. Allsop, Alfred P. Kaye, Marc N. Potenza & Gustavo A. Angarita. (2023) Changes in synaptic markers after administration of ketamine or psychedelics: a systematic scoping review. Frontiers in Psychiatry 14.
Crossref
Crossref
Rayyan Zafar, Maxim Siegel, Rebecca Harding, Tommaso Barba, Claudio Agnorelli, Shayam Suseelan, Leor Roseman, Matthew Wall, David John Nutt & David Erritzoe. (2023) Psychedelic therapy in the treatment of addiction: the past, present and future. Frontiers in Psychiatry 14.
Crossref
Crossref
Mikhail L. Zobin. (2023) Ketamin in therapy of pharmacoresistent depressions in patients with double diagnosis (naturalistic study). Neurology Bulletin L:1, pages 15-20.
Crossref
Crossref
Michael Kelson, Justin M Burnett, Amy Matthews & Tony Juneja. (2023) Ketamine Treatment for Alcohol Use Disorder: A Systematic Review. Cureus.
Crossref
Crossref
Bess M. Kew, Richard J. Porter, Katie M. Douglas, Paul Glue, Charlotte L. Mentzel & Ben Beaglehole. (2023) Ketamine and psychotherapy for the treatment of psychiatric disorders: systematic review. BJPsych Open 9:3.
Crossref
Crossref
Charlotte E. Goldfine, Jeremiah J. Tom, Dana D. Im, Benjamin Yudkoff, Amit Anand, Joseph J. Taylor, Peter R. Chai & Joji Suzuki. (2023) The therapeutic use and efficacy of ketamine in alcohol use disorder and alcohol withdrawal syndrome: a scoping review. Frontiers in Psychiatry 14.
Crossref
Crossref
Peter Sjöstedt-Hughes. (2023) On the need for metaphysics in psychedelic therapy and research. Frontiers in Psychology 14.
Crossref
Crossref
Vivian W.L. Tsang, Brendan Tao, Shannon Dames, Zach Walsh & Pam Kryskow. (2023) Safety and tolerability of intramuscular and sublingual ketamine for psychiatric treatment in the Roots To Thrive ketamine-assisted therapy program: a retrospective chart review. Therapeutic Advances in Psychopharmacology 13, pages 204512532311715.
Crossref
Crossref
Leanna J. Standish, Sonia M. Malani, Ksenia Lynch, Emily J. Whinkin, Carolyn M. McCotter, Duncan A. Lynch & Sunil K. Aggarwal. (2023) Integrative Oncology’s 30-Year Anniversary: What Have We Achieved? A North American Naturopathic Oncology Perspective. Integrative Cancer Therapies 22, pages 153473542311789.
Crossref
Crossref
Miriam Marguilho, Inês Figueiredo & Pedro Castro-Rodrigues. (2022) A unified model of ketamine’s dissociative and psychedelic properties. Journal of Psychopharmacology 37:1, pages 14-32.
Crossref
Crossref
Fahd Hilal, Jérôme Jeanblanc & Mickaël Naassila. (2023) Intérêt et mécanismes d’action de la kétamine dans le traitement de l’addiction à l’alcool – Revue des études cliniques et précliniques. Biologie Aujourd’hui 217:3-4, pages 161-182.
Crossref
Crossref
Meryem Grabski & Celia Morgan. 2023. Encyclopedia of Mental Health. Encyclopedia of Mental Health
328
335
.
Joshua Willms, Ben McCauley, Lindsay Kerr, Peyton Presto, Ankith Arun, Nazeen Shah, Kierra Irby, Megan Strawn & Jonathan Kopel. (2022) Case report: Medical student types journals during ketamine infusions for suicidal ideation, treatment-resistant depression, post-traumatic stress disorder, and generalized anxiety disorder. Frontiers in Psychiatry 13.
Crossref
Crossref
Christina Driver, Timothy N.W. Jackson, Jim Lagopoulos & Daniel F. Hermens. (2022) Molecular mechanisms underlying the N-methyl-d-aspartate receptor antagonists: Highlighting their potential for transdiagnostic therapeutics. Progress in Neuro-Psychopharmacology and Biological Psychiatry 119, pages 110609.
Crossref
Crossref
Mikhail L. Zobin. (2022) Some theoretical models of addictive disorder are used for behavioral transformation. Neurology Bulletin LIV:3, pages 51-61.
Crossref
Crossref
Sascha B Thal, Michelle Wieberneit, Jason M Sharbanee, Petra M Skeffington, Paris Baker, Raimondo Bruno, Tobias Wenge & Stephen J Bright. (2022) Therapeutic (Sub)stance: Current practice and therapeutic conduct in preparatory sessions in substance-assisted psychotherapy—A systematized review. Journal of Psychopharmacology 36:11, pages 1191-1207.
Crossref
Crossref
Sanket B. Raut, Padmaja A. Marathe, Liza van Eijk, Rajaraman Eri, Manoj Ravindran, David M. Benedek, Robert J. Ursano, Juan J. Canales & Luke R. Johnson. (2022) Diverse therapeutic developments for post-traumatic stress disorder (PTSD) indicate common mechanisms of memory modulation. Pharmacology & Therapeutics 239, pages 108195.
Crossref
Crossref
Amber N. Edinoff, Natalie W. Wu, Catherine A. Nix, Bryce Bonin, Rama Mouhaffel, Stephen Vining, William Gibson, Elyse M. Cornett, Kevin S. Murnane, Adam M. Kaye & Alan D. Kaye. (2022) Historical Pathways for Opioid Addiction, Withdrawal with Traditional and Alternative Treatment Options with Ketamine, Cannabinoids, and Noribogaine: A Narrative Review. Health Psychology Research 10:4.
Crossref
Crossref
Fernando Espí Forcén, Laura Marengo & Maya Behn. (2022) Ketamine-assisted meaning-centered psychotherapy for a patient with severe suicidal behavior. Palliative and Supportive Care, pages 1-3.
Crossref
Crossref
Isak Joneborg, Yena Lee, Joshua D. Di Vincenzo, Felicia Ceban, Shakila Meshkat, Leanna M.W. Lui, Farhan Fancy, Joshua D. Rosenblat & Roger S. McIntyre. (2022) Active mechanisms of ketamine-assisted psychotherapy: A systematic review. Journal of Affective Disorders 315, pages 105-112.
Crossref
Crossref
Nicolas Garel, Christina McAnulty, Kyle T. Greenway, Paul Lesperance, Jean-Philippe Miron, Soham Rej, Stephane Richard-Devantoy & Didier Jutras-Aswad. (2022) Efficacy of ketamine intervention to decrease alcohol use, cravings, and withdrawal symptoms in adults with problematic alcohol use or alcohol use disorder: A systematic review and comprehensive analysis of mechanism of actions.. Drug and Alcohol Dependence 239, pages 109606.
Crossref
Crossref
Fúlvio Rieli Mendes, Cristiane dos Santos Costa, Victor Distefano Wiltenburg, Gabriela Morales-Lima, João Ariel Bonar Fernandes & Renato Filev. (2022) Classic and non‐classic psychedelics for substance use disorder: A review of their historic, past and current research. Addiction Neuroscience 3, pages 100025.
Crossref
Crossref
Kwonmok Ko, Gemma Knight, James J. Rucker & Anthony J. Cleare. (2022) Psychedelics, Mystical Experience, and Therapeutic Efficacy: A Systematic Review. Frontiers in Psychiatry 13.
Crossref
Crossref
Mauro Cavarra, Alessandra Falzone, Johannes G. Ramaekers, Kim P. C. Kuypers & Carmela Mento. (2022) Psychedelic-Assisted Psychotherapy—A Systematic Review of Associated Psychological Interventions. Frontiers in Psychology 13.
Crossref
Crossref
H. Bottemanne, A. Baldacci, C. Muller, A. Boyreau & A. Claret. (2022) Psychothérapie augmentée par la kétamine (KAP) dans les troubles de l’humeur : mode d’emploi. L'Encéphale 48:3, pages 304-312.
Crossref
Crossref
Raquel Bennett, Christian Yavorsky & Gary Bravo. (2022) Ketamine for Bipolar Depression: Biochemical, Psychotherapeutic, and Psychedelic Approaches. Frontiers in Psychiatry 13.
Crossref
Crossref
David S. Mathai, Victoria Mora & Albert Garcia-Romeu. (2022) Toward Synergies of Ketamine and Psychotherapy. Frontiers in Psychology 13.
Crossref
Crossref
Sherry-Anne Muscat, Glenn Hartelius, Courtenay Richards Crouch & Kevin W. Morin. (2022) Optimized Clinical Strategies for Treatment-Resistant Depression: Integrating Ketamine Protocols with Trauma- and Attachment-Informed Psychotherapy. Psych 4:1, pages 119-141.
Crossref
Crossref
Meryem GrabskiAmy McAndrewWill LawnBeth MarshLaura RaymenTobias StevensLorna HardyFiona WarrenMichael BloomfieldAnya BorissovaEmily MaschauerRupert BroombyRobert PriceRachel CoathupDavid GilhoolyEdward PalmerRichard Gordon-WilliamsRobert HillJen HarrisO. Merve MollaahmetogluH. Valerie CurranBrigitta BrandnerAnne Lingford-HughesCelia J.A. Morgan. (2022) Adjunctive Ketamine With Relapse Prevention–Based Psychological Therapy in the Treatment of Alcohol Use Disorder. American Journal of Psychiatry 179:2, pages 152-162.
Crossref
Crossref
Zach Walsh, Ozden Merve Mollaahmetoglu, Joseph Rootman, Shannon Golsof, Johanna Keeler, Beth Marsh, David J. Nutt & Celia J. A. Morgan. (2021) Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review. BJPsych Open 8:1.
Crossref
Crossref
Nina Schimmers, Joost J. Breeksema, Sanne Y. Smith-Apeldoorn, Jolien Veraart, Wim van den Brink & Robert A. Schoevers. (2021) Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review. Psychopharmacology 239:1, pages 15-33.
Crossref
Crossref
Sherry-Anne Muscat, Glenn Hartelius, Courtenay Richards Crouch & Kevin W. Morin. (2021) An Integrative Approach to Ketamine Therapy May Enhance Multiple Dimensions of Efficacy: Improving Therapeutic Outcomes With Treatment Resistant Depression. Frontiers in Psychiatry 12.
Crossref
Crossref
Anya Ragnhildstveit, Laura Kate Jackson, Sarah Cunningham, Linda Good, Quinn Tanner, Matthew Roughan & Patricia Henrie-Barrus. (2021) Case Report: Unexpected Remission From Extreme and Enduring Bulimia Nervosa With Repeated Ketamine Assisted Psychotherapy. Frontiers in Psychiatry 12.
Crossref
Crossref
Michael Koslowski, Matthew W. Johnson, Gerhard Gründer & Felix Betzler. (2021) Novel Treatment Approaches for Substance Use Disorders: Therapeutic Use of Psychedelics and the Role of Psychotherapy. Current Addiction Reports 9:1, pages 48-58.
Crossref
Crossref
John Martin Corkery, Wan-Chu Hung, Hugh Claridge, Christine Goodair, Caroline S Copeland & Fabrizio Schifano. (2021) Recreational ketamine-related deaths notified to the National Programme on Substance Abuse Deaths, England, 1997–2019. Journal of Psychopharmacology 35:11, pages 1324-1348.
Crossref
Crossref
David S. Mathai, Alexis G. McCathernAndrew G. GuzickSophie C. Schneider, Saira A. WeinzimmerSandra L. CepedaAlbert Garcia-RomeuEric A. Storch. (2021) Parental Attitudes Toward Use of Ketamine in Adolescent Mood Disorders and Suicidality. Journal of Child and Adolescent Psychopharmacology 31:8, pages 553-561.
Crossref
Crossref
O. Merve Mollaahmetoglu, Johanna Keeler, Katherine J. Ashbullby, Eirini Ketzitzidou-Argyri, Meryem Grabski & Celia J. A. Morgan. (2021) “This Is Something That Changed My Life”: A Qualitative Study of Patients' Experiences in a Clinical Trial of Ketamine Treatment for Alcohol Use Disorders. Frontiers in Psychiatry 12.
Crossref
Crossref
Rachael L Sumner, Emme Chacko, Rebecca McMillan, Meg J Spriggs, Christie Anderson, James Chen, Amelia French, SungHun Jung, Akshaya Rajan, Gemma Malpas, John Hay, Rhys Ponton, Suresh D Muthukumaraswamy & Frederick Sundram. (2021) A qualitative and quantitative account of patient’s experiences of ketamine and its antidepressant properties. Journal of Psychopharmacology 35:8, pages 946-961.
Crossref
Crossref
Sascha B. Thal, Stephen J. Bright, Jason M. Sharbanee, Tobias Wenge & Petra M. Skeffington. (2021) Current Perspective on the Therapeutic Preset for Substance-Assisted Psychotherapy. Frontiers in Psychology 12.
Crossref
Crossref
Sandeep Nayak & Matthew W. Johnson. (2020) Psychedelics and Psychotherapy. Pharmacopsychiatry 54:04, pages 167-175.
Crossref
Crossref
Giovanni Martinotti, Stefania Chiappini, Mauro Pettorruso, Alessio Mosca, Andrea Miuli, Francesco Di Carlo, Giacomo D’Andrea, Roberta Collevecchio, Ilenia Di Muzio, Stefano L. Sensi & Massimo Di Giannantonio. (2021) Therapeutic Potentials of Ketamine and Esketamine in Obsessive–Compulsive Disorder (OCD), Substance Use Disorders (SUD) and Eating Disorders (ED): A Review of the Current Literature. Brain Sciences 11:7, pages 856.
Crossref
Crossref
Radosław Stupak & Bartłomiej Dobroczyński. (2021) From Mental Health Industry to Humane Care. Suggestions for an Alternative Systemic Approach to Distress. International Journal of Environmental Research and Public Health 18:12, pages 6625.
Crossref
Crossref
Samuel Kohtala. (2021) Ketamine—50 years in use: from anesthesia to rapid antidepressant effects and neurobiological mechanisms. Pharmacological Reports 73:2, pages 323-345.
Crossref
Crossref
Kabir B. Nigam & Ananda K. Pandurangi. (2021) Do Hallucinogens Have a Role in the Treatment of Addictions? A Review of the Current Literature. SN Comprehensive Clinical Medicine 3:6, pages 1385-1395.
Crossref
Crossref
Rebecca L Rothberg, Nour Azhari, Nancy A Haug & Elias Dakwar. (2020) Mystical-type experiences occasioned by ketamine mediate its impact on at-risk drinking: Results from a randomized, controlled trial. Journal of Psychopharmacology 35:2, pages 150-158.
Crossref
Crossref
Umesh Pathak, SunilKumar Ahuja, Rajeev Dwivedi, Nimisha Mishra, Pradeep Kumar, DheerendraKumar Mishra & Rajesh Singh. (2021) Antisuicidal efficacy of ketamine infusion in suicidal patients of depressive disorder. Indian Journal of Psychiatry 63:5, pages 483.
Crossref
Crossref
Russ Curtis, Lisen Roberts, Elizabeth Graves, Heather Thompson Rainey, David Wynn, David Krantz & Verena Wieloch. (2020) The Role of Psychedelics and Counseling in Mental Health Treatment. Journal of Mental Health Counseling 42:4, pages 323-338.
Crossref
Crossref
Keith A. Trujillo & Sergio D. Iñiguez. (2020) Ketamine beyond anesthesia: Antidepressant effects and abuse potential. Behavioural Brain Research 394, pages 112841.
Crossref
Crossref
Joost J. Breeksema, Alistair R. Niemeijer, Erwin Krediet, Eric Vermetten & Robert A. Schoevers. (2020) Psychedelic Treatments for Psychiatric Disorders: A Systematic Review and Thematic Synthesis of Patient Experiences in Qualitative Studies. CNS Drugs 34:9, pages 925-946.
Crossref
Crossref
Meryem Grabski, Anna Borissova, Beth Marsh, Celia J.A. Morgan & H.Valerie Curran. (2020) Ketamine as a mental health treatment: Are acute psychoactive effects associated with outcomes? A systematic review. Behavioural Brain Research 392, pages 112629.
Crossref
Crossref
Daniela Franco, Jennifer Zamudio, Kennedy M. Blevins, Eric A. Núñez-Larios, Ulises M. Ricoy, Sergio D. Iñiguez & Arturo R. Zavala. (2020) Early-life ketamine exposure attenuates the preference for ethanol in adolescent Sprague-Dawley rats. Behavioural Brain Research 389, pages 112626.
Crossref
Crossref
Erwin Krediet, Tijmen Bostoen, Joost Breeksema, Annette van Schagen, Torsten Passie & Eric Vermetten. (2020) Reviewing the Potential of Psychedelics for the Treatment of PTSD. International Journal of Neuropsychopharmacology 23:6, pages 385-400.
Crossref
Crossref
Radosław Stupak. (2020) Model biomedyczny w psychopatologii. Krytyczny szkic historyczny, współczesny kontekst i problemy etyczne. Diametros, pages 1-18.
Crossref
Crossref
Greer McKendrick, Hannah Garrett, Holly E. Jones, Dillon S. McDevitt, Sonakshi Sharma, Yuval Silberman & Nicholas M. Graziane. (2020) Ketamine Blocks Morphine-Induced Conditioned Place Preference and Anxiety-Like Behaviors in Mice. Frontiers in Behavioral Neuroscience 14.
Crossref
Crossref
Abby Pribish, Nicole Wood & Arun Kalava. (2020) A Review of Nonanesthetic Uses of Ketamine. Anesthesiology Research and Practice 2020, pages 1-15.
Crossref
Crossref
David S. Mathai, Matthew J. Meyer, Eric A. Storch & Thomas R. Kosten. (2020) The relationship between subjective effects induced by a single dose of ketamine and treatment response in patients with major depressive disorder: A systematic review. Journal of Affective Disorders 264, pages 123-129.
Crossref
Crossref
Elias DakwarFrances LevinCarl L. HartCale BasarabaJean ChoiMartina PavlicovaEdward V. Nunes. (2020) A Single Ketamine Infusion Combined With Motivational Enhancement Therapy for Alcohol Use Disorder: A Randomized Midazolam-Controlled Pilot Trial. American Journal of Psychiatry 177:2, pages 125-133.
Crossref
Crossref
Elias DakwarEdward V. NunesCarl L. HartRichard W. FoltinSanjay J. MathewKenneth M. CarpenterC.J. “Jean” ChoiCale N. BasarabaMartina PavlicovaFrances R. Levin. (2019) A Single Ketamine Infusion Combined With Mindfulness-Based Behavioral Modification to Treat Cocaine Dependence: A Randomized Clinical Trial. American Journal of Psychiatry 176:11, pages 923-930.
Crossref
Crossref
Agata Nowacka & Malgorzata Borczyk. (2019) Ketamine applications beyond anesthesia – A literature review. European Journal of Pharmacology 860, pages 172547.
Crossref
Crossref
MATTHEW J. BEGOLA & JASON E. SCHILLERSTROM. (2019) Hallucinogens and Their Therapeutic Use: A Literature Review. Journal of Psychiatric Practice 25:5, pages 334-346.
Crossref
Crossref
Muhammad N. IqbalCharles J. LevinFrances R. Levin. (2019) Treatment for Substance Use Disorder With Co-Occurring Mental Illness. FOCUS 17:2, pages 88-97.
Crossref
Crossref
R. Das, G. Gale, K. Walsh, V. Hennessy, G. Iskandar, L. Mordecai, B. Brandner, M. Kindt, L. Otten, V. Curran & S. Kamboj. (2019) Ketamine reduces alcohol consumption in hazardous drinkers by interfering with the reconsolidation of drinking memories: Preliminary findings. European Neuropsychopharmacology 29, pages S486-S487.
Crossref
Crossref
David J. Heal, Jack Henningfield, Bruno G. Frenguelli, David J. Nutt & Sharon L. Smith. (2018) Psychedelics – Re-opening the doors of perception. Neuropharmacology 142, pages 1-6.
Crossref
Crossref
David J. Heal, Jane Gosden & Sharon L. Smith. (2018) Evaluating the abuse potential of psychedelic drugs as part of the safety pharmacology assessment for medical use in humans. Neuropharmacology 142, pages 89-115.
Crossref
Crossref
I. Ivan Ezquerra-Romano, W. Lawn, E. Krupitsky & C.J.A. Morgan. (2018) Ketamine for the treatment of addiction: Evidence and potential mechanisms. Neuropharmacology 142, pages 72-82.
Crossref
Crossref
E. Dakwar, E.V. Nunes, C.L. Hart, M.C. Hu, R.W. Foltin & F.R. Levin. (2018) A sub-set of psychoactive effects may be critical to the behavioral impact of ketamine on cocaine use disorder: Results from a randomized, controlled laboratory study. Neuropharmacology 142, pages 270-276.
Crossref
Crossref
Edward.M. Sellers, Myroslava K. Romach & Deborah B. Leiderman. (2018) Studies with psychedelic drugs in human volunteers. Neuropharmacology 142, pages 116-134.
Crossref
Crossref
Ben Sessa. (2018) Why MDMA therapy for alcohol use disorder? And why now?. Neuropharmacology 142, pages 83-88.
Crossref
Crossref
Siddharth Jha, Silven Read, Peter Hurd & Bernard Crespi. (2018) Segregating polymorphism in the NMDA receptor gene GRIN2A, schizotypy, and mental rotation among healthy individuals. Neuropsychologia 117, pages 347-351.
Crossref
Crossref
Jennifer L. Jones, Camilo F. Mateus, Robert J. Malcolm, Kathleen T. Brady & Sudie E. Back. (2018) Efficacy of Ketamine in the Treatment of Substance Use Disorders: A Systematic Review. Frontiers in Psychiatry 9.
Crossref
Crossref
Eduardo Ekman Schenberg. (2018) Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development. Frontiers in Pharmacology 9.
Crossref
Crossref
Peter Eischens & William Leigh Atherton. (2018) Psychedelic therapy as a complementary treatment approach for alcohol use disorders. Journal of Psychedelic Studies 2:1, pages 36-44.
Crossref
Crossref
Christian Sueur. (2018) État des lieux de la recherche sur les capacités thérapeutiques des « substances hallucinogènes » au 21 e siècle. Psychotropes Vol. 23:3, pages 125-163.
Crossref
Crossref
Marc F. Ettensohn, Sara M. Markey & Steven P. Levine. (2018) Considering Ketamine for Treatment of Comorbid Pain, Depression, and Substance Use Disorders. Psychiatric Annals 48:4, pages 180-183.
Crossref
Crossref
Elizabeth M. Nielson, Darrick G. May, Alyssa A. Forcehimes & Michael P. Bogenschutz. (2018) The Psychedelic Debriefing in Alcohol Dependence Treatment: Illustrating Key Change Phenomena through Qualitative Content Analysis of Clinical Sessions. Frontiers in Pharmacology 9.
Crossref
Crossref
Ben Sessa. (2017) The 21st century psychedelic renaissance: heroic steps forward on the back of an elephant. Psychopharmacology 235:2, pages 551-560.
Crossref
Crossref
Ben Sessa. 2018. Handbuch Psychoaktive Substanzen. Handbuch Psychoaktive Substanzen
83
104
.
Felix Betzler & Tomislav Majić. 2018. Handbuch Psychoaktive Substanzen. Handbuch Psychoaktive Substanzen
683
699
.
Amy McAndrew, Will Lawn, Tobias Stevens, Lilla Porffy, Brigitta Brandner & Celia J. A. Morgan. (2017) A proof-of-concept investigation into ketamine as a pharmacological treatment for alcohol dependence: study protocol for a randomised controlled trial. Trials 18:1.
Crossref
Crossref
Michael P. Bogenschutz & Alyssa A. Forcehimes. (2016) Development of a Psychotherapeutic Model for Psilocybin-Assisted Treatment of Alcoholism. Journal of Humanistic Psychology 57:4, pages 389-414.
Crossref
Crossref
Ben Sessa. (2017) Why Psychiatry Needs 3,4-Methylenedioxymethamphetamine: A Child Psychiatrist's Perspective. Neurotherapeutics 14:3, pages 741-749.
Crossref
Crossref
Ben Sessa. (2017) Can 3,4,-methylenedioxymethamphetamine therapy be used to treat alcohol use disorder?. Journal of Psychedelic Studies 1:1, pages 1-9.
Crossref
Crossref
Celia Morgan, Amy McAndrew, Tobias Stevens, David Nutt & Will Lawn. (2017) Tripping up addiction: the use of psychedelic drugs in the treatment of problematic drug and alcohol use. Current Opinion in Behavioral Sciences 13, pages 71-76.
Crossref
Crossref
E Dakwar, C L Hart, F R Levin, E V Nunes & R W Foltin. (2016) Cocaine self-administration disrupted by the N-methyl-D-aspartate receptor antagonist ketamine: a randomized, crossover trial. Molecular Psychiatry 22:1, pages 76-81.
Crossref
Crossref
Steven J. Pennybaker, Mark J. Niciu, David A. Luckenbaugh & Carlos A. Zarate. (2017) Symptomatology and predictors of antidepressant efficacy in extended responders to a single ketamine infusion. Journal of Affective Disorders 208, pages 560-566.
Crossref
Crossref
Ben Sessa. 2017. Handbuch Psychoaktive Substanzen. Handbuch Psychoaktive Substanzen
1
29
.
Yu Liu, Deyong Lin, Boliang Wu & Wenhua Zhou. (2016) Ketamine abuse potential and use disorder. Brain Research Bulletin 126, pages 68-73.
Crossref
Crossref
Elias Dakwar & Edward V. Nunes. (2016) New Directions in Medication-Facilitated Behavioral Treatment for Substance Use Disorders. Current Psychiatry Reports 18:7.
Crossref
Crossref
Rafael G. dos Santos, Flávia L. Osório, José Alexandre S. Crippa, Jordi Riba, Antônio W. Zuardi & Jaime E. C. Hallak. (2016) Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years. Therapeutic Advances in Psychopharmacology 6:3, pages 193-213.
Crossref
Crossref
Keith G. Rasmussen. (2016) Has psychiatry tamed the “ketamine tiger?” Considerations on its use for depression and anxiety. Progress in Neuro-Psychopharmacology and Biological Psychiatry 64, pages 218-224.
Crossref
Crossref
Daniel Flack & Elias Dakwar. 2016. Neuropathology of Drug Addictions and Substance Misuse. Neuropathology of Drug Addictions and Substance Misuse
681
688
.
Luís Félix, Luís Antunes, Sónia Campos, Carlos Venâncio & Ana Maria Coimbra. 2016. Neuropathology of Drug Addictions and Substance Misuse. Neuropathology of Drug Addictions and Substance Misuse
672
680
.
Ben Sessa. 2016. Handbuch Psychoaktive Substanzen. Handbuch Psychoaktive Substanzen
1
26
.
Felix Betzler & Tomislav Majić. 2017. Handbuch Psychoaktive Substanzen. Handbuch Psychoaktive Substanzen
1
22
.
Carolyn Ines Rodriguez & Elias Dakwar. 2016. Ketamine for Treatment-Resistant Depression. Ketamine for Treatment-Resistant Depression
137
155
.
Ravi K. Das, Chandni Hindocha, Tom P. Freeman, Antonio I. Lazzarino, H. Valerie Curran & Sunjeev K. Kamboj. (2015) Assessing the translational feasibility of pharmacological drug memory reconsolidation blockade with memantine in quitting smokers. Psychopharmacology 232:18, pages 3363-3374.
Crossref
Crossref
Tomislav Majić, Timo T Schmidt & Jürgen Gallinat. (2015) Peak experiences and the afterglow phenomenon: When and how do therapeutic effects of hallucinogens depend on psychedelic experiences?. Journal of Psychopharmacology 29:3, pages 241-253.
Crossref
Crossref
Ben Sessa & Matthew W. Johnson. (2018) Can psychedelic compounds play a part in drug dependence
therapy?. British Journal of Psychiatry 206:1, pages 1-3.
Crossref
Crossref
Adrian Wong, Neal J. Benedict, Michael J. Armahizer & Sandra L. Kane-Gill. (2014) Evaluation of Adjunctive Ketamine to Benzodiazepines for Management of Alcohol Withdrawal Syndrome. Annals of Pharmacotherapy 49:1, pages 14-19.
Crossref
Crossref
James X. Liu, Erin Zerbo & Stephen Ross. (2015) Intensive ketamine use for multiple years: A case report. The American Journal on Addictions 24:1, pages 7-9.
Crossref
Crossref
Ben Sessa. (2015) Turn on and tune in to evidence-based psychedelic research. The Lancet Psychiatry 2:1, pages 10-12.
Crossref
Crossref
Elias Dakwar. 2015. Textbook of Addiction Treatment: International Perspectives. Textbook of Addiction Treatment: International Perspectives
713
730
.
Elias Dakwar, Frances Levin, Richard W. Foltin, Edward V. Nunes & Carl L. Hart. (2014) The Effects of Subanesthetic Ketamine Infusions on Motivation to Quit and Cue-Induced Craving in Cocaine-Dependent Research Volunteers. Biological Psychiatry 76:1, pages 40-46.
Crossref
Crossref
E. Dakwar, C. Anerella, C.L. Hart, F.R. Levin, S.J. Mathew & E.V. Nunes. (2014) Therapeutic infusions of ketamine: Do the psychoactive effects matter?. Drug and Alcohol Dependence 136, pages 153-157.
Crossref
Crossref
Ornella Corazza, Sulaf Assi & Fabrizio Schifano. (2013)
From “Special
K
” to “Special
M
”: The Evolution of the Recreational Use of Ketamine and Methoxetamine
. CNS Neuroscience & Therapeutics 19:6, pages 454-460.
Crossref
Crossref
Celia J. A. Morgan & H. Valerie Curran. (2011) Ketamine use: a review. Addiction 107:1, pages 27-38.
Crossref
Crossref
Stephen Ross & Eric Peselow. (2009) The Neurobiology of Addictive Disorders. Clinical Neuropharmacology 32:5, pages 269-276.
Crossref
Crossref
Robin L Carhart-Harris, Helen S Mayberg, Andrea L Malizia & David Nutt. (2008) Mourning and melancholia revisited: correspondences between principles of Freudian metapsychology and empirical findings in neuropsychiatry. Annals of General Psychiatry 7:1.
Crossref
Crossref
Hylke Vervaeke. 2008. Drugs en alcohol; Gebruik, misbruik en verslaving. Drugs en alcohol; Gebruik, misbruik en verslaving
369
406
.
John C.M. Brust. 2007. Aspects neurologiques de l'addiction. Aspects neurologiques de l'addiction
385
516
.
Kim Wolff & Adam R Winstock. (2006) Ketamine. CNS Drugs 20:3, pages 199-218.
Crossref
Crossref
Jan Copeland & Paul Dillon. (2005) The health and psycho-social consequences of ketamine use. International Journal of Drug Policy 16:2, pages 122-131.
Crossref
Crossref
Mary Tod Gray. (2016) Philosophical Inquiry in Nursing: An Argument for Radical Empiricism as a Philosophical Framework for the Phenomenology of Addiction. Qualitative Health Research 14:8, pages 1151-1164.
Crossref
Crossref
John C.M. Brust. 2004. Neurological Aspects of Substance Abuse. Neurological Aspects of Substance Abuse
317
425
.
C. Ori, M. Dalsasso & U. Freo. 2004. Anaesthesia, Pain, Intensive Care and Emergency Medicine — A.P.I.C.E.. Anaesthesia, Pain, Intensive Care and Emergency Medicine — A.P.I.C.E.
863
879
.
John H. Halpern. (2003) Hallucinogens: An update. Current Psychiatry Reports 5:5, pages 347-354.
Crossref
Crossref
Axel Becker, Brigitte Peters, Helmut Schroeder, Tobias Mann, Gerald Huether & Gisela Grecksch. (2003) Ketamine-induced changes in rat behaviour: A possible animal model of schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry 27:4, pages 687-700.
Crossref
Crossref
Fernando Caudevilla Gálligo. (2003) Cartas al Editor. Medicina Clínica 121:8, pages 318-319.
Crossref
Crossref
Evgeny Krupitsky, Andrey Burakov, Tatyana Romanova, Igor Dunaevsky, Rick Strassman & Alexander Grinenko. (2002) Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up. Journal of Substance Abuse Treatment 23:4, pages 273-283.
Crossref
Crossref
Francisca Charliane Carlos Da Silva, Rodrigo Tavares Dantas, Maria d do Carmo de Oliveira Citó, Silvânia Maria Mendes De Vasconcelos, Marta Maria de França Fonteles, Glauce Socorro de Barros Viana & Francisca Cléa Florenço De Sousa. (2001) Ketamina, da anestesia ao uso abusivo. Revista Neurociências 18:2, pages 227-237.
Crossref
Crossref